Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betamethasone diproprionate/calcipotriol - LEO Pharma

Drug Profile

Betamethasone diproprionate/calcipotriol - LEO Pharma

Alternative Names: Calcipotriene/betamethasone propionate; Calcipotriol/betamethasone diproprionate; Daivobet; Daivobet 50/500 Ointment; Daivobet Gel; Dovobet; Enstilar; LEO 90105; LEO-80185; LEO-90100; LEO90100 cutaneous spray; LP-0113; Taclonex; Taclonex Scalp; Xamiol

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEO Pharma
  • Developer Kyowa Kirin; LEO Pharma
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriasis

Most Recent Events

  • 01 Aug 2019 Registered for Plaque psoriasis (In adolescents) in USA (Topical, Foam)
  • 01 Aug 2019 The US FDA approves betamethasone dipropionate and calcipotriene for scalp and body Plaque psoriasis (In adolescents) in USA (Topical, Suspension)
  • 26 Jun 2019 LEO Pharma completes the PSO-LONG phase III trial for Plaque psoriasis in USA, United Kingdom, Canada, France, Germany, Poland (Topical, Foam) (NCT02899962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top